Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD

2.11  -0.14 (-6.22%)

After market: 2.15 +0.04 (+1.9%)

Fundamental Rating

2

Taking everything into account, INO scores 2 out of 10 in our fundamental rating. INO was compared to 558 industry peers in the Biotechnology industry. INO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, INO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.
INO had a negative operating cash flow in the past year.
INO had negative earnings in each of the past 5 years.
In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -110.55%, INO is doing worse than 79.39% of the companies in the same industry.
INO has a Return On Equity of -188.25%. This is in the lower half of the industry: INO underperforms 66.85% of its industry peers.
Industry RankSector Rank
ROA -110.55%
ROE -188.25%
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INO has more shares outstanding
INO has more shares outstanding than it did 5 years ago.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

INO has an Altman-Z score of -30.09. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
INO's Altman-Z score of -30.09 is on the low side compared to the rest of the industry. INO is outperformed by 90.14% of its industry peers.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -30.09
ROIC/WACCN/A
WACC8.55%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.63 indicates that INO has no problem at all paying its short term obligations.
The Current ratio of INO (2.63) is worse than 68.46% of its industry peers.
INO has a Quick Ratio of 2.63. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
INO has a Quick ratio of 2.63. This is in the lower half of the industry: INO underperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.63
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.32% over the past year.
INO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.52%.
INO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -44.44% yearly.
EPS 1Y (TTM)44.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.7%
Revenue 1Y (TTM)-60.52%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.96% on average per year.
Based on estimates for the next years, INO will show a very strong growth in Revenue. The Revenue will grow by 356.19% on average per year.
EPS Next Y47.63%
EPS Next 2Y24.35%
EPS Next 3Y21.09%
EPS Next 5Y17.96%
Revenue Next Year2978.38%
Revenue Next 2Y1169.62%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INO. In the last year negative earnings were reported.
Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

INO's earnings are expected to grow with 21.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.35%
EPS Next 3Y21.09%

More info and screens

0

5. Dividend

5.1 Amount

INO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (6/27/2025, 8:23:22 PM)

After market: 2.15 +0.04 (+1.9%)

2.11

-0.14 (-6.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06
Inst Owners37.34%
Inst Owner Change2.6%
Ins Owners0.74%
Ins Owner Change2.77%
Market Cap77.37M
Analysts80
Price Target8.16 (286.73%)
Short Float %18.05%
Short Ratio10.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.01%
Min EPS beat(2)29.03%
Max EPS beat(2)44.99%
EPS beat(4)3
Avg EPS beat(4)22.62%
Min EPS beat(4)-6.95%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)10.42%
EPS beat(12)6
Avg EPS beat(12)4.5%
EPS beat(16)7
Avg EPS beat(16)-3.01%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.13%
PT rev (3m)-15.79%
EPS NQ rev (1m)6.21%
EPS NQ rev (3m)6.92%
EPS NY rev (1m)10.18%
EPS NY rev (3m)29.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)26.32%
Revenue NY rev (3m)48.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 273.31
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-3.09
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-2.8
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.01
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.55%
ROE -188.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.83%
Cap/Sales 180.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.63
Altman-Z -30.09
F-Score1
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)16.84%
Cap/Depr(5y)25.5%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.7%
EPS Next Y47.63%
EPS Next 2Y24.35%
EPS Next 3Y21.09%
EPS Next 5Y17.96%
Revenue 1Y (TTM)-60.52%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A
Revenue Next Year2978.38%
Revenue Next 2Y1169.62%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%
EBIT growth 1Y10.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.5%
OCF growth 3YN/A
OCF growth 5YN/A